46 results about "Toxic dose" patented technology

A method for the treatment of myeloma and thymoma by administering a therapeutically effective dose of Mycobacterium indicus pranii with Cyclophosphamide. This disclosure generally relates to the field of cancer biology. More specifically, this disclosure relates to the immunotherapeutic treatment of myeloma and thymoma, using a combination of heat killed Mycobacterium indicus pranii and the widely administered chemotherapeutic drug, Cyclophosphamide. Mycobacterium indicus pranii has already shown its efficacy as an immunomodulator and has been safely administered to humans. The most common method of cancer management is the application of chemotherapeutic drugs which results in side-effects. At lower non-toxic doses Cyclophosphamide is not effective. The present disclosure discloses a method of improving efficacy of non-toxic doses of Cyclophosphamide by administrating it together with Mycobacterium indicus pranii. This disclosure is relevant for the treatment of other lymphomas as well.

A stent for implanting in the body to hold open a blood vessel includes cells with facing loops and the curved flexible links disposed and adapted to cooperate so that, when unexpanded, the stent can flex as it is moved through curved blood vessels to a site where it is to be expanded and so that, when the stent is expanded in a curved vessel, at that site, as compared to each other, cells on the outside of the curve are open in length, but narrow in width as compared to cells on the inside of the curve which are short in length but increased in width to result in a more constant stent cell area between the inside and the outside of the curve than would otherwise occur causing the stent, when coated with a medicine, to apply a more even dose to the inside wall of the lumen, avoiding the possibility that a toxic dose is supplied at one area while a less than effective dose is applied to another area.

An intravascular stent especially suited for implanting in curved arterial portions. The stent retains longitudinal flexibility after expansion. The stent is formed of intertwined meander patterns forming triangular cells. The triangular cells are adapted to provide radial support, and also to provide longitudinal flexibility after expansion. The triangular cells provide increased coverage of a vessel wall. The stent can have different portions adapted to optimize radial support or to optimize longitudinal flexibility. Loops in the stent are disposed and adapted to cooperate so that after expansion of said stent within a curved lumen, the stent is curved and cells on the outside of the curve open in length, but narrow in width whereas cells on the inside of the curve shorten in length but thicken in width to maintain a density of stent element area which much more constant than otherwise between the inside and the outside of the curve. As a result, when the stent is coated with a medicine the more constant density of stent elements results in an even dose being applied to the inside wall of the lumen, avoiding the possibility that a toxic dose be supplied at one area while a less than effective dose is applied to another area.

The invention relates to novel application of methylene blue to post-anesthesia awakening. The novel application is characterized in that after an animal is completely anesthetized, a certain dose of the methylene blue can be injected to the animal, so that awakening of the animal can be accelerated, the anesthesia time is shortened, and overdose anesthesia can be reduced to a certain extent; the novel application of the methylene blue is beneficial to relieving and resisting the overdose anesthesia by the aid of the methylene blue in animal experiments and clinical application; the experimental animal is anesthetized by the aid of pentobarbital sodium with certain concentration, then methylene blue solution with certain concentration is injected to the completely anesthetized animal, and the concentration of the methylene blue solution is lower than a toxic dose of the methylene blue; then the awakening time of the animal is observed, and an awakening effect of the methylene blue is judged after the awakening effect of the methylene blue is compared with an awakening effect of normal saline; as shown by experiment results, the required time for awakening the animal after the animal is anesthetized by the aid of the pentobarbital sodium can be obviously shortened by the aid of the methylene blue solution, an awakening latency stage can be shortened, and the overdose anesthesia can be reduced. The novel application of the methylene blue has the advantages that a safe, convenient and speedy awakening measure is hopefully provided for clinical application, and possible injury to patients due to the overdose anesthesia can be reduced.